Prediabetes Commonly Missed Diagnoses: What Gets Overlooked and Why It Matters

Why Prediabetes Goes Undetected So Often

Prediabetes occupies a diagnostic gray zone. Blood sugar is elevated enough to cause early microvascular damage but not high enough to trigger the clinical urgency that overt diabetes does. As a result, clinicians may order a fasting glucose and stop there, missing the subset of patients whose glucose is only abnormal after a meal.

The Centers for Disease Control and Prevention estimates that 98 million American adults have prediabetes and that more than 8 in 10 are unaware of their status. [1] That gap is not primarily a patient-awareness problem. It reflects incomplete laboratory workup, over-reliance on a single test, and competing diagnoses that cloud the picture.

The Three-Test Problem

The American Diabetes Association (ADA) recognizes three independent diagnostic criteria for prediabetes. [2] A patient can meet one criterion while failing the others. A fasting glucose of 99 mg/dL is technically normal, yet the same patient might post a 2-hour OGTT value of 158 mg/dL, squarely in the impaired glucose tolerance (IGT) range. Because the OGTT is time-consuming and rarely ordered outside endocrinology, that patient leaves the office without a diagnosis.

The three thresholds:

• Impaired fasting glucose (IFG): fasting plasma glucose 100 to 125 mg/dL
• Impaired glucose tolerance (IGT): 2-hour glucose 140 to 199 mg/dL on a 75-gram OGTT
• Borderline A1c: hemoglobin A1c 5.7 to 6.4 percent

A 2019 analysis published in Diabetes Care found that IFG and IGT identify largely non-overlapping populations, meaning exclusive reliance on fasting glucose misses a substantial fraction of people with true glucose dysregulation. [3]

Screening Who Gets Missed

USPSTF guidelines recommend screening adults aged 35 to 70 who have overweight or obesity (BMI 25 to 29.9 or BMI ≥30). [4] That threshold excludes younger adults with polycystic ovary syndrome (PCOS), lean individuals with strong family history, and people of South Asian or East Asian ancestry, all groups with elevated risk at lower BMI thresholds. The ADA extends screening to any adult aged 45 or older regardless of weight, and to younger adults with any single risk factor. [2]

Conditions That Are Commonly Confused With Prediabetes

Several clinical entities either mimic prediabetes on laboratory tests or co-exist with it in ways that delay the correct label.

Stress Hyperglycemia

Transient glucose elevation during acute illness, surgery, or psychological stress is well documented. A single fasting glucose of 108 mg/dL drawn during a hospitalization for pneumonia does not confirm prediabetes. The ADA explicitly states that diagnosis should not be made from a single abnormal value obtained during acute stress unless symptoms of frank diabetes are present. [2] Re-testing 4 to 8 weeks after the acute event is the standard approach, yet that follow-up is missed in a substantial proportion of patients who are discharged with a note of "elevated glucose, recheck outpatient."

Medication-Induced Glucose Elevation

Multiple commonly prescribed drug classes raise fasting or postprandial glucose to prediabetic levels:

• Glucocorticoids (prednisone, dexamethasone): raise postprandial glucose more than fasting; OGTT or continuous glucose monitoring may be needed to capture the full picture
• Atypical antipsychotics (olanzapine, quetiapine): associated with insulin resistance independent of weight gain, per a meta-analysis in JAMA Psychiatry [5]
• Thiazide diuretics at doses above 25 mg hydrochlorothiazide equivalents
• Tacrolimus and cyclosporine in transplant patients: cause post-transplant diabetes mellitus in 10 to 40 percent of recipients [6]
• High-dose niacin and protease inhibitors used in HIV management

When a patient on one of these agents shows a borderline A1c, the clinician faces a genuine diagnostic ambiguity: is this drug-induced transient hyperglycemia or underlying prediabetes that the drug has unmasked? The practical answer is to repeat testing after the offending agent is tapered, if clinically feasible, and to apply clinical judgment about underlying metabolic risk.

Polycystic Ovary Syndrome

PCOS is the most common endocrine disorder in reproductive-age women, affecting 8 to 13 percent of this group by WHO estimates. [7] Insulin resistance is a core feature, not simply a side effect of weight. Studies using OGTT in women with PCOS show that up to 35 percent have IGT or IFG, yet many clinicians check only a fasting glucose and A1c, both of which can be normal in early insulin-resistant states. The result: a PCOS patient receives metformin for cycle regulation but never receives the formal prediabetes label that would trigger lifestyle counseling and metabolic monitoring.

Reactive Hypoglycemia

Reactive (postprandial) hypoglycemia produces glucose values that fall below 70 mg/dL two to four hours after eating, often preceded by a postprandial spike into the prediabetic range. Patients present with shakiness, anxiety, and fatigue after meals. If only the symptomatic trough is captured, the preceding glucose spike (which may reach 160 to 180 mg/dL) is missed, and the clinician attributes everything to hypoglycemia alone. Continuous glucose monitoring (CGM) for 10 to 14 days is the most informative approach in this scenario, simultaneously documenting any postprandial hyperglycemia and the subsequent drop.

A1c Interference Conditions

Hemoglobin A1c is a convenient but imperfect marker. The following conditions produce falsely low or falsely high A1c values, potentially masking or fabricating a prediabetes diagnosis:

| Condition | Direction of A1c Error | |---|---| | Iron-deficiency anemia | Falsely elevated | | Hemolytic anemia | Falsely low | | Hemoglobin S, C, or E variants | Variable (assay-dependent) | | Chronic kidney disease (GFR <60) | Falsely low | | Recent blood transfusion | Falsely low | | Vitamin B12 or folate deficiency | Falsely elevated |

In patients with any of these conditions, fasting plasma glucose or the OGTT should be used as the primary diagnostic tool. The National Glycohemoglobin Standardization Program certifies assays for interference, but point-of-care A1c devices are not always NGSP-certified. [8]

A1c Versus OGTT: Choosing the Right Test

The choice between A1c and OGTT is not arbitrary. Each test captures a different physiological window.

What A1c Detects

A1c reflects average glucose over the prior 8 to 12 weeks. It is reproducible, does not require fasting, and is affected by erythrocyte lifespan. In a population with normal red-cell turnover and no hemoglobin variants, it is a reliable screening tool. A 2021 study in Diabetes Care (N=9,000 from the NHANES cohort) found that A1c alone missed 29 percent of individuals who would have been classified as prediabetic by OGTT. [9]

What the OGTT Adds

The 75-gram OGTT captures postprandial glucose handling, which is the earliest physiological abnormality in the progression toward type 2 diabetes. Beta-cell dysfunction and early hepatic insulin resistance manifest first as impaired glucose disposal after a carbohydrate load, often years before fasting glucose climbs. The OGTT is the reference standard in pregnancy screening for gestational diabetes, which explains why GDM diagnoses are rarely missed, while the same underlying glucose dysregulation outside of pregnancy often goes unlabeled.

When to Use Each

For routine outpatient screening in metabolically straightforward patients, A1c and fasting glucose together catch the majority of prediabetes cases. Add an OGTT when: the patient has PCOS, the A1c is borderline but the clinical picture suggests higher risk, a hemoglobin variant is present, or the patient has symptoms of postprandial dysglycemia (excessive hunger, energy crashes after meals, or history of GDM).

Prediabetes vs. Early Type 2 Diabetes: Where the Line Blurs

The boundary between prediabetes and early type 2 diabetes is a single laboratory threshold: fasting glucose 126 mg/dL or A1c 6.5 percent. Both conditions share the same pathophysiology, and the division is partly administrative. What matters clinically is that the diagnostic label changes the treatment conversation significantly.

A patient with A1c 6.3 percent is classified as prediabetic under current ADA criteria, but may already have subclinical retinopathy. A landmark analysis of NHANES data showed that retinopathy prevalence begins to rise at A1c levels well below the diabetes threshold, suggesting the cutpoints are somewhat arbitrary from a tissue-damage perspective. [10]

The practical implication: patients near the upper end of the prediabetes range (A1c 6.0 to 6.4 percent, fasting glucose 115 to 125 mg/dL) warrant treatment intensity approaching that used in early type 2 diabetes, even if the formal label is still "prediabetes."

How to Manage Prediabetes: Evidence-Based Steps

Prediabetes is reversible. The Diabetes Prevention Program (DPP) randomized 3,234 adults with IFG and IGT to intensive lifestyle intervention, metformin 850 mg twice daily, or placebo. The lifestyle arm achieved a 58 percent reduction in progression to type 2 diabetes at 3 years; the metformin arm achieved 31 percent reduction. [11]

Lifestyle Modification

The DPP lifestyle protocol targeted a 7 percent reduction in body weight and at least 150 minutes per week of moderate-intensity physical activity (equivalent to brisk walking). Weight loss of 5 to 7 percent is the minimum threshold associated with meaningful metabolic benefit. Dietary composition mattered less than total caloric restriction in the DPP, though low-glycemic-index and Mediterranean-pattern diets show consistent benefits in secondary analyses.

Resistance training adds an independent effect: a meta-analysis in Diabetes Care covering 12 randomized trials found that resistance exercise alone reduced A1c by 0.48 percentage points in people with dysglycemia. [12]

Pharmacotherapy

The ADA recommends metformin as the preferred pharmacotherapy for prediabetes in adults who:

• Have BMI ≥35
• Are younger than 60 years
• Have a history of gestational diabetes mellitus
• Show A1c rising despite lifestyle changes, particularly when A1c exceeds 6.0 percent [2]

Metformin is started at 500 mg once daily with the evening meal and titrated to 850 mg twice daily over 4 to 8 weeks to minimize gastrointestinal side effects. The ADA Standards of Medical Care in Diabetes 2024 states: "Metformin is the most cost-effective pharmacotherapy for diabetes prevention and should be considered in adults at very high risk for diabetes." [2]

GLP-1 receptor agonists are emerging as an option in prediabetes with obesity. Semaglutide 2.4 mg weekly (Wegovy) reduced body weight by 14.9 percent at 68 weeks in the STEP-1 trial (N=1,961), with a large proportion of participants having prediabetes at baseline. [13] Post-hoc analysis of STEP-1 showed that 84.1 percent of participants who had prediabetes at baseline reverted to normoglycemia by week 68 in the semaglutide group, compared with 47.8 percent in the placebo group. [13] As of this writing, semaglutide is not FDA-approved with a labeled indication for prediabetes prevention, but it is prescribed off-label in this context at many academic centers.

Monitoring and Follow-Up

After a prediabetes diagnosis, repeat A1c and fasting glucose every 6 to 12 months. Patients who achieve normoglycemia (A1c <5.7 percent, fasting glucose <100 mg/dL) on lifestyle changes may space monitoring to once yearly, but the ADA notes that regression to normoglycemia does not eliminate risk, and a long-term surveillance schedule is still warranted. [2]

Lipids, blood pressure, and kidney function (serum creatinine plus urine albumin-to-creatinine ratio) should be assessed at diagnosis and annually, because cardiovascular risk is elevated in prediabetes independently of whether progression to diabetes occurs.

The Role of Continuous Glucose Monitoring in Clarifying Ambiguous Cases

CGM has moved from a diabetes-management tool to a diagnostic adjunct in metabolically ambiguous cases. A 14-day blinded CGM trace shows:

• Time in range (70 to 140 mg/dL)
• Postprandial spikes that traditional labs miss
• The presence of reactive hypoglycemia alongside hyperglycemic excursions
• Nocturnal glucose patterns that may explain unexplained weight gain or fatigue

A study in JAMA Internal Medicine demonstrated that CGM identified glucose abnormalities in a substantial fraction of individuals with normal A1c and fasting glucose, particularly those with high-carbohydrate diets. [14] CGM does not replace the OGTT for formal diagnostic classification, but it builds a compelling clinical narrative that motivates behavior change in patients who are skeptical of abstract lab numbers.

When to Refer to Endocrinology

Most prediabetes management can occur in primary care. Refer to endocrinology when:

• A1c is 6.2 percent or above and not declining with 6 months of lifestyle modification
• The patient has a first-degree relative with MODY (maturity-onset diabetes of the young) or type 1 diabetes, raising the question of autoimmune etiology
• An A1c interference condition is suspected and OGTT interpretation is unclear
• The patient has PCOS with complex hormonal management needs
• GLP-1 therapy or bariatric evaluation is being considered and the primary care clinician is not comfortable managing these options

The ADA position statement on referral does not set a specific A1c threshold for endocrinology consultation, but clinical practice guidelines from the American Association of Clinical Endocrinology (AACE) support co-management when lifestyle and metformin have both failed to arrest A1c progression. [15]

Summary Data Table: Prediabetes Diagnostic Thresholds vs. Lookalike Conditions

| Finding | Prediabetes | Type 2 Diabetes | Stress Hyperglycemia | Medication-Induced | |---|---|---|---|---| | Fasting glucose | 100 to 125 mg/dL | ≥126 mg/dL | Variable, often <126 | Variable | | A1c | 5.7 to 6.4% | ≥6.5% | Usually normal after recovery | May be elevated | | OGTT 2-hr | 140 to 199 mg/dL | ≥200 mg/dL | Not diagnostic acutely | Variable | | Repeat testing confirms | Yes | Yes | No (reverts) | Partial (drug-dependent) | | A1c reliability | Standard unless variant | Standard | Normal | May be unreliable |